New drug aimed at shoulder pain fails to complete trial
NCT ID NCT05758415
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug secukinumab against a placebo in 60 adults with moderate to severe rotator cuff tendinopathy, a painful shoulder condition. The goal was to see if secukinumab could improve symptoms and shoulder function over 24 weeks. However, the trial was terminated early, so its findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
secukinumab
What this could lead to
If successful, secukinumab could offer a new treatment option to reduce pain and improve shoulder function in people with rotator cuff tendinopathy.
What could go wrong
The trial was terminated early with only 60 participants, so results are limited. As a phase 3 study, it may still fail to show benefit or have side effects like infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROTATOR CUFF TENDINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Conquest Research
Winter Park, Florida, 32789, United States
-
Horizon Clinical Research
La Mesa, California, 91942, United States
-
LV Research
Las Vegas, Nevada, 89119, United States
-
Medvin Clinical Research
Van Nuys, California, 91405, United States
-
Novartis Investigative Site
Wuhan, CHN, 430033, China
-
Novartis Investigative Site
Shijiazhuang, Hebei, 050051, China
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Xian, Shanxi, 710004, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Shanghai, 200040, China
-
Novartis Investigative Site
Milan, MI, 20157, Italy
-
Novartis Investigative Site
Siena, SI, 53100, Italy
-
Novartis Investigative Site
Krakow, 31-141, Poland
-
Novartis Investigative Site
Swidnica, 85-100, Poland
-
Novartis Investigative Site
Torun, 87-100, Poland
-
Novartis Investigative Site
Warsaw, 00-874, Poland
-
Novartis Investigative Site
Warsaw, 02-677, Poland
-
Novartis Investigative Site
Santiago, A Coruna, 15705, Spain
-
Novartis Investigative Site
Sabadell, Barcelona, 08208, Spain
-
Novartis Investigative Site
A Coruña, 15006, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Valencia, 46024, Spain
-
Novartis Investigative Site
Bangkok, 10400, Thailand
-
Novartis Investigative Site
Chiang Mai, 50200, Thailand